Back to Clinical Case Reviews

The importance of reporting discrete HER2 IHC scores

Case contributed by Marilyn Bui, MD, PhD

Marilyn Bui

MD, PhD

Case details

Age
58
Gender
Female

Tumor grade
Initial biopsy: Grade 2
Lumpectomy: Grade 3
(Glandular/tubular formation score: 3/3
Nuclear pleomorphism score: 3/3
Mitotic rate score: 2/3)
Overall score: 8/9
Specimen type in primary setting
Biopsy left breast
Type of breast cancer
Invasive ductal carcinoma with lobular features
Hormone receptor status
ER: Positive (90%)
PR: Positive (30%)
HER2 by IHC
Negative (discrete IHC not reported)
Treatment received
Lumpectomy followed by radiation
therapy
Patient stopped treatment with hormone
therapy
Disease progression
Two years later, PET/CT scan showed multiple enlarged left internal mammary lymph nodes and following a biopsy, metastatic carcinoma of the breast was identified

Type of breast cancer
Left breast invasive ductal carcinoma with lobular features
Hormone receptor status
ER: Negative
PR: Negative
HER2 by IHC
Equivocal (2+)
HER2 by CISH
Negative (not amplified)
Pre-analytic variables and technical issues
None

In this case, the patient presented with a primary breast cancer classified as HER2-negative. This was a referral case and the discrete HER2 IHC score was not reported from the outside institution. Following progression of the disease, the patient’s metastatic sample was found to be HER2 IHC 2+ (equivocal), with negative CISH, which also categorized the metastatic sample as HER2-negative. From primary to metastatic disease, the change in HER2 IHC score was unknown; the score may have changed from either IHC 0 to IHC 2+, or IHC 1+ to IHC 2+. This case highlights the importance of reporting discrete HER2 IHC scores, as opposed to binary HER2-positive or -negative results.

Case summary

A biopsy and subsequent left breast lumpectomy were performed at an outside institution on a 58-year-old female, and she was found to have invasive ductal carcinoma with lobular features. After HER2 IHC evaluation, the tumor was reported to be HER2-negative with no subsequent reflex ISH testing. No discrete IHC score was provided in the referral report, and therefore, it was not possible to determine whether the sample was HER2 0 or 1+ by IHC. The patient was then treated with radiotherapy as well as hormone therapy; however, hormone therapy was stopped secondary to side effects.

Two years later, a PET/CT scan showed multiple enlarged left internal mammary lymph nodes with increased FDG avidity, suggestive of metastatic disease. A CT-guided biopsy of a left internal mammary node was performed. The biopsy identified metastatic carcinoma of the breast (positive CK7 and GATA3 by IHC). The tumor was scored as HER2 IHC 2+. FISH could not be performed due to insufficient sample. Chemotherapy was initiated.

Following treatment with chemotherapy, a CT-guided biopsy of the left chest wall again showed metastatic disease of breast origin (positive CK7 and GATA3 by IHC). HER2 IHC evaluation was performed and was scored as IHC 2+ with negative CISH.

Figure 1. Left chest wall metastasis. a. H&E stain (20X). b. HER2 IHC stain (IHC 2+, 20X).

View whole slide image

What does the HER2 IHC staining indicate?

The specimen from CT-guided biopsy of the left chest wall metastatic breast cancer (Figure 1) shows complete membrane staining of moderate intensity in >10% of tumor cells, and therefore, was scored as HER2 IHC 2+. CISH was performed and was negative (HER2/CEP17 ratio = 1.26, HER2 copy = 2.40, and CEP17 copy = 1.90).

The interpretation was made following the 2018 ASCO-CAP HER2 guidelines, which state that equivocal IHC (2+) is weak-to-moderate complete membrane staining in >10% of tumor cells, or complete/circumferential membrane staining that is intense in ≤10% of the invasive tumor cells.¹

A supporting visual guide for HER2 differentiation can help with HER2 IHC assessment in clinical practice. The guide can be found here.

Discussion

In this case, although both primary and metastatic samples were HER2-negative, the difference in HER2 IHC score was unknown; the score may have changed from either IHC 0 to IHC 2+, or IHC 1+ to IHC 2+. This case highlights the importance of reporting discrete HER2 IHC scores as opposed to binary HER2-positive or -negative results. Reporting the discrete score provides a higher level of information, which is especially helpful to compare with if further testing occurs in a patient’s disease course.

As we now recognize the full spectrum of HER2 expression, providing discrete IHC scores in the pathology report is key to gaining a better overall understanding of a patient’s disease. Having detailed biomarker information at all stages of a patient’s journey with breast cancer may help to better inform clinical care and treatment decisions.

Considerations

HER2 IHC scores can differ between primary and metastatic samples. According to the 2023 ASCO-CAP guideline update, HER2 IHC testing should be repeated on metastatic specimens¹
Include discrete HER2 IHC scores in the pathology report*

You can find more information on how to approach similar challenging cases in the e-learning series titled Interpreting HER2 in breast cancer: A full spectrum of possibilities, found in the Breast Cancer Resources.

*These practice considerations represent the opinions of the Breast Pathology Faculty. Members of the Breast Pathology Faculty have been contracted as paid advisors through Daiichi Sankyo and AstraZeneca and have received compensation for their time.

ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; CEP17, chromosome enumeration probe 17; CISH, chromogenic in situ hybridization; CK7, cytokeratin 7; CT, computed tomography; CISH, chromogenic in situ hybridization; ER, estrogen receptor; FDG, fluorodeoxyglucose; FISH, fluorescence in situ hybridization; GATA3, GATA binding protein 3; H&E, hematoxylin and eosin stain; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; PET, positron emission tomography; PR, progesterone receptor.

1. Wolff AC, et al. Arch Pathol Lab Med. 2023;147(9):993-1000.

Did you find this content useful?
Help us get it right next time by liking this article

Explore more Clinical Case Reviews

View all

In this series of articles, the Pathology Faculty share their experience with complex clinical cases and highlight practices that help to aid consistency in HER2 IHC scoring.

View all

Assessing HER2 IHC with cytoplasmic staining

In this case, the HER2 IHC on a segmental mastectomy specimen from a primary invasive ductal carcinoma showed an unusual cytoplasmic staining pattern.

by Savitri Krishnamurthy, MD

Assessing HER2 IHC with edge artifacts

In this case, the HER2 IHC of a core needle biopsy specimen from an invasive breast carcinoma showed signs of edge artifact.

by Gary Tozbikian, MD

Interpreting HER2 IHC with an extensive in situ component

In this case, there was an extensive in situ component present along with the invasive carcinoma, and HER2 IHC scores were discordant between the two.

by Hannah Wen, MD, PhD

The importance of reporting discrete HER2 IHC scores

Marilyn Bui

MD, PhD

Case details

Age

Gender

Tumor grade

Specimen type in primary setting

Type of breast cancer

Hormone receptor status

HER2 by IHC

Treatment received

Disease progression

Type of breast cancer

Hormone receptor status

HER2 by IHC

HER2 by CISH

Pre-analytic variables and technical issues

Case summary

Figure 1. Left chest wall metastasis. a. H&E stain (20X). b. HER2 IHC stain (IHC 2+, 20X).

What does the HER2 IHC staining indicate?

Discussion

Considerations

Explore more Clinical Case Reviews

Assessing HER2 IHC with cytoplasmic staining

In this case, the HER2 IHC on a segmental mastectomy specimen from a primary invasive ductal carcinoma showed an unusual cytoplasmic staining pattern.

Assessing HER2 IHC with edge artifacts

In this case, the HER2 IHC of a core needle biopsy specimen from an invasive breast carcinoma showed signs of edge artifact.

Interpreting HER2 IHC with an extensive in situ component

In this case, there was an extensive in situ component present along with the invasive carcinoma, and HER2 IHC scores were discordant between the two.

Quick Links

Breast Cancer Links

Gastric Cancer Links

About Us

Legal

What is a Daiichi Sankyo Company or AstraZeneca authorized person?

The importance of reporting discrete HER2 IHC scores

Marilyn Bui

MD, PhD

Case details

Patient information

Age

Gender

Sample of primary tumor

Tumor grade

Specimen type in primary setting

Type of breast cancer

Hormone receptor status

HER2 by IHC

Treatment received

Disease progression

Sample of metastatic tumor – left internal mammary lymph node

Type of breast cancer

Hormone receptor status

HER2 by IHC

HER2 by CISH

Pre-analytic variables and technical issues

Case summary

Figure 1. Left chest wall metastasis. a. H&E stain (20X). b. HER2 IHC stain (IHC 2+, 20X).

What does the HER2 IHC staining indicate?

Discussion

Considerations

Explore more Clinical Case Reviews

Assessing HER2 IHC with cytoplasmic staining

In this case, the HER2 IHC on a segmental mastectomy specimen from a primary invasive ductal carcinoma showed an unusual cytoplasmic staining pattern.

Assessing HER2 IHC with edge artifacts

In this case, the HER2 IHC of a core needle biopsy specimen from an invasive breast carcinoma showed signs of edge artifact.

Interpreting HER2 IHC with an extensive in situ component

In this case, there was an extensive in situ component present along with the invasive carcinoma, and HER2 IHC scores were discordant between the two.

Quick Links

Breast Cancer Links

Gastric Cancer Links

About Us

Legal

What is a Daiichi Sankyo Company or AstraZeneca authorized person?